Cancer Drug Lapatinib Offers Safer HER2 Route for Patients With Failing Hearts
A new clinical case report shows that the oral HER2 inhibitor lapatinib, with its short half-life and low cardiac toxicity, ...
A new clinical case report shows that the oral HER2 inhibitor lapatinib, with its short half-life and low cardiac toxicity, ...
Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm Follow' to start subscribing.
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine